Earnings Releases·Nov 9, 2026, 4:50 PM ET

Novanta — Third Quarter 2026 Earnings Summary

GAAP revenue rose 23% year-over-year to $305 million, driven by a 13.3% acquisition impact and 9.9% organic growth, while GAAP net income and diluted EPS declined to $2.0 million and $0.05, respectively, from $10.7 million and $0.30 in the prior year; conversely, Adjusted EBITDA surged 38% to $80.3 million and Adjusted Diluted EPS increased 21% to $1.05.
The company raised full-year 2026 GAAP revenue guidance to $1,135–$1,140 million and Adjusted EBITDA to $274–$277 million, projecting 16% reported revenue growth and approximately 7% organic growth for the year.
Novanta closed its largest-ever acquisition, Riverpoint Medical, contributing $32.9 million to revenue and increasing total debt to $829.8 million (up from $250.8 million) and net debt to $689.4 million (from a prior net cash position of $121.3 million).
Strategic momentum remains strong with customer bookings up 29% year-over-year and backlog expanding to $543 million, supporting a 2027 reported revenue growth expectation of more than 15%.